AstraZeneca invests $4.5 billion in new plant in Virginia, responding to Trump’s call for more U.S. drug manufacturing. Site will be company’s largest globally, creating 600 jobs with 3,000 during construction. Expansion includes cancer drugs and future medications, costing $500 million more. Analysts question political motives behind industry moves.

Trump’s pressure prompts Pfizer to lower drug prices in exchange for tariff relief. AstraZeneca CEO Soriot navigates demands, listing shares on NYSE and offering discounts on diabetes and asthma drugs. Virginia plant aims to boost U.S. security and health sovereignty. Critics doubt impact on revenues and prices, suggesting political motives.

Read more at Yahoo Finance: AstraZeneca breaks ground at $4.5 billion Virginia plant as drugmakers court Trump